Welcome to our dedicated page for Intellia Therapeutics SEC filings (Ticker: NTLA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Intellia Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Intellia Therapeutics's regulatory disclosures and financial reporting.
Contrarius Investment Management Limited and Contrarius Investment Management (Bermuda) Limited report beneficial ownership of 714,480 shares of Intellia Therapeutics, Inc.0.6% of the class as of the event date.
The firms have shared voting and dispositive power over all 714,480 shares and no sole power. They state that the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Intellia. The filing is made jointly because the two entities may be deemed a group under section 13(d)(3).
State Street Corporation has filed a Schedule 13G reporting beneficial ownership of Intellia Therapeutics common stock. It reports beneficial ownership of 6,418,836 shares, representing 5.5% of the outstanding common stock as of the event date.
State Street reports no sole voting or dispositive power, with shared voting power over 6,045,757 shares and shared dispositive power over 6,418,836 shares. The holdings are reported as being acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Intellia. Several State Street Global Advisors and related investment adviser subsidiaries are identified as relevant entities.
ARK Investment Management LLC and its founder Catherine D. Wood report beneficial ownership of 14,207,324 shares of Intellia Therapeutics, Inc. common stock, representing 12.27% of the class as of 12/31/2025.
ARK has sole voting power over 13,162,242 shares and shared voting power over 280,265 shares. It has sole dispositive power over all 14,207,324 shares. Wood is reported to share voting power over 13,442,507 shares and share dispositive power over all 14,207,324 shares through her control of ARK.
The filing states these securities are held in the ordinary course of business and not for the purpose of changing or influencing control of Intellia. It also notes that among ARK’s clients, only ARK Innovation ETF holds more than 5% of this class.
The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 13,010,001 shares of Intellia Therapeutics Inc common stock, representing 11.23% of the class as of 12/31/2025.
Vanguard reports shared voting power over 864,210 shares and shared dispositive power over all 13,010,001 shares, with no sole voting or dispositive power. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control of Intellia.
Vanguard also notes an internal realignment effective 01/12/2026, after which certain subsidiaries or business divisions that are deemed to have beneficial ownership may report their holdings separately, while continuing the same investment strategies.
Intellia Therapeutics reports that the U.S. FDA has removed the clinical hold on the investigational new drug application for its MAGNITUDE-2 Phase 3 trial of nexiguran ziclumeran ("nex-z") in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). The FDA had placed MAGNITUDE-2 and the related MAGNITUDE Phase 3 cardiomyopathy (ATTR-) trial on hold after a MAGNITUDE patient experienced Grade 4 liver transaminase elevations with increased total bilirubin and subsequently died, triggering protocol-defined pausing criteria. Intellia has now agreed with the FDA on study modifications and mitigation measures, including enhanced liver safety monitoring, and is working with investigators, ethics committees, regulators and other stakeholders to restart enrollment in MAGNITUDE-2.
The FDA clinical hold on the MAGNITUDE Phase 3 trial in ATTR- remains in place, and Intellia’s engagement with the agency on a path forward for that program is ongoing. The company plans to provide an update once alignment with the FDA is reached on next steps for the cardiomyopathy trial.
Intellia Therapeutics reported safety updates from its Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nexiguran ziclumeran ("nex-z") for transthyretin amyloidosis. A previously disclosed patient in MAGNITUDE experienced Grade 4 liver transaminase elevations and increased bilirubin, triggering a protocol-defined pause, and the FDA placed a clinical hold on the nex-z Phase 3 programs. The patient later died on November 5, 2025, with the principal investigator attributing the death to septic shock secondary to a perforated duodenal ulcer, with a clinical course that included acute liver injury treated with corticosteroids and supported by autopsy findings.
More than 650 patients with ATTR-CM are enrolled in MAGNITUDE and 47 patients with hereditary ATTRv-PN are enrolled in MAGNITUDE-2. Grade 4 liver transaminase elevations have occurred in less than one percent of MAGNITUDE patients, with no such events in MAGNITUDE-2, and all cases except the fatal one resolved within weeks without reported clinical sequelae. The company also updated its corporate presentation for investor and analyst meetings and plans to provide a further update after finalizing a path forward for nex-z with regulators.
Intellia Therapeutics, Inc. President and CEO John M. Leonard, who is also a director, reported a mandatory sell-to-cover stock transaction. On January 5, 2026, he sold 34,146 shares of common stock at $9.21 per share to cover tax withholding obligations arising from the vesting of restricted stock units on January 1, 2026. The filing states this was not a voluntary trade. After this transaction, Leonard beneficially owned 1,013,339 common shares directly and an additional 58,415 common shares indirectly held by the John M. Leonard 2015 Irrevocable Trust.
Intellia Therapeutics EVP and Chief Scientific Officer Birgit C. Schultes reported a mandatory tax-related stock sale. On January 5, 2026, she sold 8,508 shares of Intellia Therapeutics common stock at a price of $9.21 per share. A footnote explains this was a required “sell-to-cover” transaction to satisfy tax withholding obligations upon the vesting of restricted stock units on January 1, 2026, and not a voluntary trade. Following this transaction, she beneficially owned 98,533 shares of Intellia common stock, which include 925 and 932 shares acquired under the company’s 2016 Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, respectively.
Intellia Therapeutics executive James Basta reported a tax-related stock sale. On January 5, 2026, he sold 10,397 shares of Intellia Therapeutics common stock at a price of $9.21 per share. According to the filing, this was a mandatory “sell-to-cover” transaction to satisfy his tax withholding obligation from restricted stock units that vested on January 1, 2026, and it is explicitly described as not a voluntary trade. After this transaction, he beneficially owned 101,528 shares of Intellia common stock directly.
Intellia Therapeutics, Inc. director Fred E. Cohen reported an open market purchase of the company’s common stock. On January 5, 2026, he bought 150,000 shares of common stock at a weighted average price of $9.35 per share, coded as a purchase transaction.
According to the filing, these shares were acquired in multiple trades at prices ranging from $9.13 to $9.68. Following this transaction, Cohen beneficially owns 207,453 shares of Intellia Therapeutics common stock held directly.